Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

L-citrulline intravenous - Asklepion Pharmaceuticals/Vanderbilt-University

Next Previous
Drug Profile

L-citrulline intravenous - Asklepion Pharmaceuticals/Vanderbilt-University

Alternative Names: L-citrulline; Turnobi

Latest Information Update: 03 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vanderbilt University
  • Developer Asklepion Pharmaceuticals; Vanderbilt University
  • Class Amino acids; Diamino amino acids; Small molecules
  • Mechanism of Action Amino acid replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute lung injury
  • Phase II SARS-CoV-2 acute respiratory disease
  • Phase I/II Vaso-occlusive crisis

Most Recent Events

  • 29 Jun 2022 Asklepion Pharmaceuticals initiates a phase III trial for Acute lung injury (Prevention, In infants, In children, In adolescents) in June 2022 (IV) (NCT05253209)
  • 23 Feb 2022 Asklepion Pharmaceuticals plans a phase III trial for Acute lung injury (Prevention, In infants, In children, In adolescents) in April 2022 (IV) (NCT05253209)
  • 03 Feb 2022 Asklepion Pharmaceuticals completes a phase II trial in SARS-COV-2 acute respiratory disease in USA (IV) (NCT04570384)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top